|
Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM). |
|
Miguel Angel Villalona-Calero |
Consulting or Advisory Role - Lilly |
Research Funding - Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Merck (Inst); Novocure (Inst); Tolero Pharmaceuticals (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - Celgene |
|
|
Honoraria - Intuitive Surgical |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Lilly |
Speakers' Bureau - Boehringer Ingelheim; Lilly |
|
|
|
No Relationships to Disclose |
|
|
Research Funding - Incyte |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen; AVEO; Celcuity; Exelixis; NeoGenomics Laboratories; Seagen; Sellas Life Sciences; Tesaro |
Speakers' Bureau - Amgen; Boehringer Ingelheim; Celgene; Celgene; Eisai; Exelixis; Guardant Health; Janssen Oncology; Seagen; Takeda |
|
|
No Relationships to Disclose |